Background Respiratory viruses are the leading cause of lower respiratory tract infection
(LRTI) and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is …

Objective Palivizumab is a humanized monoclonal antibody approved for the prevention of
serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in …

The introduction of nirsevimab (a respiratory syncytial virus [RSV] monoclonal antibody that
can protect for minimum 5 months with a single dose) and RSV maternal vaccines to protect …

Premature birth is a major contributor to under-five mortality, causing approximately 1 million
deaths every year. This vulnerability stems from the high susceptibility of neonates …

FORMAL EVIDENCE-BASED AND EXPERT CONSENSUS ON IMMUNOPROPHYLAXIS
WITH PALIVIZUMAB IN PATIENTS WITH CONGENITAL HEART DISEASE Page 1 Órgano …